Beta Bionics logo — Working to improve the lives of people living with diabetes...

Beta Bionics

Working to improve the lives of people living with diabetes and help reduce the data and decision-making overload.

Founded 2015 United States Irvine, United States 255 employees Series D Total: $293.45M Biotechnology, Medical Devices

General Information

Company Name Beta Bionics
Founded Year 2015
Location United States Irvine, United States
Founders / Decision Makers
Team member
Employees 255
Industries Biotechnology, Medical Devices
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with Beta Bionics. To contact Beta Bionics, visit betabionics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Beta Bionics compare?

A PDF of Beta Bionics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Beta Bionics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Beta Bionics

Beta Bionics is a biotechnology and medical devices startup founded in 2015, based in the United States. The company's slogan embodies its mission of improving the lives of people living with diabetes and alleviating the burden of data and decision-making overload. Beta Bionics is focused on developing and commercializing the iLet Bionic Pancreas and the bihormonal configuration to provide innovative solutions for diabetes management. The iLet Bionic Pancreas is noteworthy as the first and only insulin delivery system that eliminates the need for carb counting, bolusing, correction factors, or pre-set basal rates. Users only need to input their weight, and the iLet takes care of the rest, simplifying the management of diabetes. The company's commitment to social impact is evident in its status as a for-profit, Certified B Corporation, emphasizing its dedication to improving health outcomes and enhancing the quality of life for individuals with diabetes and other glycemic dysregulation conditions. In a recent milestone, Beta Bionics secured a notable $100.00M Series D investment on 30th August 2023, with a diverse group of investors including Pura Vida Investments, Marshall Wace, Sands Capital Ventures, LifeSci Venture Partners, Omega Funds, Perceptive Advisors, RTW Investments, Soleus Capital, Eventide Asset Management, and Farallon Capital Management. This substantial investment reflects the confidence of prominent investors in Beta Bionics' innovative approach and its potential for making a meaningful impact in the healthcare industry.

Business keywords: diabetes management, insulin delivery system, glucose metabolism, bionic pancreas, public benefit corporation, Certified B Corporation, glycemic dysregulation, innovation, patient-focused, dasiglucagon, breakthrough technology, health outcomes

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Series D $100.00M 10
Pura Vida Investments, Marshall Wace +8
30 Aug 2023
Series C $57.00M 9
Pura Vida Investments, ArrowMark Partners +7
17 Feb 2022
Series B $63.00M 6
ArrowMark Partners, Perceptive Advisors +4
01 Jul 2019
Series B $63.00M 6
ArrowMark Partners, LifeSci Venture Partners +4
08 Jan 2019
Grant $2.00M 1
National Institute of Diabetes and Digestive and Kidney Diseases
02 Oct 2018
Venture Round $2.45M -
27 Dec 2017
Equity Crowdfunding $1.00M -
14 Jun 2016
Series A $5.00M 2
Eli Lilly, Novo Nordisk
31 Dec 2015

Beta Bionics Alternatives & Competitors

View All Alternatives
Beta Bionics vs
Valeritas
Valeritas United States

Improving health and simplifying life for people with diabetes.

Venture round
35 employees
Biotechnology, Health Care
Beta Bionics vs

Simplifying Diabetes

Series C
28 employees
Biotechnology, Health Care
Beta Bionics vs

Capillary Biomedical, Inc. (CapBio) is a medical device startup developing technologies for diabetes...

Debt Financing
10 employees
Biotechnology, Health Care

FAQ About Beta Bionics

Working to improve the lives of people living with diabetes and help reduce the data and decision-making overload.
Beta Bionics was founded in 2015.
Beta Bionics is headquartered in Irvine, United States.
Beta Bionics operates in Biotechnology and Medical Devices. Its work centres on diabetes management, insulin delivery system, glucose metabolism and bionic pancreas.
Beta Bionics has approximately 255 employees.
Beta Bionics has completed 8 funding rounds, raising a total of $293.45M. The latest funding stage is Series D.
Top alternatives and competitors to Beta Bionics include Valeritas, Medtrum Technologies Inc., Capillary Biomedical, Senseonics, Incorporated, Intuity Medical, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Beta Bionics and Valeritas are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Beta Bionics, https://bouncewatch.com/company/beta-bionics, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes